Catalog No.
Product Name
Application
Product Information
Citations
-
iNOS Inhibitor
GW274150 phosphate is a selective, orally active inhibitor of inducible nitric oxide synthase (iNOS), demonstrating potent inhibition with an IC50 of 2.19 μM and a Kd of 40 nM in human iNOS, as well as an ED50 of 1.15 μM in rat iNOS. This compound exhibits reduced potency against endothelial and neuronal NOS isoforms. GW274150 phosphate has been shown to provide protective effects in models of acute lung injury and inflammation, making it a valuable tool for researchers studying inflammatory responses and related pathways. -
NO Synthase Inhibtior
NG-nitro-L-arginine is a potent nitric oxide synthase (NOS) inhibitor, demonstrating inhibitory constants (Kis) of 0.61 μM for neuronal NOS (nNOS), 4.28 μM for inducible NOS (iNOS), and 0.72 μM for endothelial NOS (eNOS). This compound effectively inhibits the formation and release of endothelium-derived relaxing factor (EDRF), making it a valuable tool in cardiovascular research. NG-nitro-L-arginine has been shown to reduce portal-systemic shunting in portal-hypertensive rat models and is associated with increased blood pressure, thereby serving as a key reagent for studies investigating vascular function and regulation. -
NO Synthase Inhibitor
Kuwanon A is a flavone derivative that serves as an inhibitor of nitric oxide synthase. It effectively reduces nitric oxide production with an IC50 of 10.5 μM. This compound is relevant for research applications investigating vascular function, inflammatory processes, and the pathophysiology of various diseases linked to nitric oxide signaling. -
NOS Inhibitor
S-MTC dihydrochloride is a selective inhibitor of type I nitric oxide synthase (NOS). It effectively reduces nitric oxide production, making it a valuable tool for studies investigating the role of NOS in various physiological and pathological processes. This compound is commonly utilized in research applications related to cardiovascular health, neurobiology, and inflammation. -
nNOS Inhibitor
Nω-Propyl-L-arginine is a highly selective and potent competitive inhibitor of neuronal nitric oxide synthase (nNOS), exhibiting a Ki value of 57 nM. With a 149-fold selectivity for nNOS over endothelial nitric oxide synthase (eNOS), this compound is invaluable for studying nNOS-related pathways and neurobiology. Its use is pertinent in elucidating the role of nNOS in various physiological and pathological processes, making it a crucial reagent for research applications in neuroscience and pharmacology. -
nitric oxide synthase Inhibitor
Aminopicoline is a potent and non-selective inhibitor of nitric oxide synthase (NOS) isoenzymes, including iNOS, nNOS, and eNOS. By competing with arginine at the substrate-binding site, it effectively reduces cellular nitric oxide production and inhibits the elevation of plasma nitrate levels, which can influence mean arterial pressure. This compound serves as a valuable tool in research focused on diseases related to septic shock, joint and intestinal inflammation, as well as central nervous system (CNS) inflammation. -
NO Synthase Antagonist
L-NMMA (N-methyl-L-arginine) is a competitive antagonist of L-arginine that effectively inhibits the production of nitric oxide (NO) by targeting nitric oxide synthase. This compound is employed in various experimental studies to investigate the physiological and pathological roles of NO and its signaling pathways. Its application extends to cardiovascular research, neurobiology, and studies involving vascular function. -
NOS3 Inhibitors
Kihadanin A is a limonoid that functions as an inhibitor of nitric oxide synthase 3 (NOS3). Isolated from the methanol extract of Dictamnus dasycarpus root bark, Kihadanin A demonstrates potential therapeutic applications in the study of hyperuricemia (HUA). This compound can be utilized in research aimed at understanding the biochemical pathways related to nitric oxide production and its implications in various physiological conditions. -
NOS Inhibitor
nNOS-IN-1 is a selective inhibitor of nitric oxide synthases (NOS), demonstrating potent inhibitory activity against neuronal, inducible, and endothelial NOS with IC50 values of 2.5, 5.7, and 13 μM, respectively. This compound serves as a valuable tool for elucidating the roles of nitric oxide in various biological processes and has potential applications in neurobiology and cardiovascular research. By selectively targeting NOS, nNOS-IN-1 can aid in the investigation of pathological conditions associated with dysregulated nitric oxide signaling. -
nNOS Inhibitor
Nω-Propyl-L-arginine hydrochloride is a selective inhibitor of neuronal nitric oxide synthase (nNOS), exhibiting a competitive inhibition profile with a Ki value of 57 nM. This compound offers significant selectivity, displaying a 149-fold preference for nNOS over endothelial nitric oxide synthase (eNOS). Nω-Propyl-L-arginine hydrochloride is primarily utilized in research applications focused on the modulation of nitric oxide pathways and the study of nNOS-related physiological and pathological processes. -
NO Synthase Inhibitor
2-Iminobiotin hydrobromide is a reversible inhibitor of nitric oxide synthase (NOS), specifically exhibiting Kis of 21.8 μM for murine inducible NOS (iNOS) and 37.5 μM for rat neuronal NOS (n-cNOS). This compound has demonstrated potential neuroprotective effects, providing protection to human neuronal cells against hypoxia-induced cell damage. It is valuable for research in neurobiology and the study of nitric oxide signaling pathways. -
iNOS Inhibitor
AR-C102222 hydrochloride is a selective inhibitor of inducible nitric oxide synthase (iNOS) with a competitive mechanism of action. Demonstrating an IC50 of 37 nM, it exhibits notable antinociceptive and anti-inflammatory properties. This compound is valuable for research into pain modulation and inflammatory diseases, providing insights into the role of nitric oxide in these biological processes. -
iNOS Inhibitor
BBS-4 is a highly potent and selective inhibitor of inducible nitric oxide synthase (iNOS, NOS2) dimerization, demonstrating an IC50 of 0.49 nM. This compound is primarily utilized in research focused on cardiovascular dysfunction, notably offering protective effects in murine models of sepsis. Its selective inhibition of iNOS makes BBS-4 a valuable tool for investigating nitric oxide-related pathologies and potential therapeutic interventions. -
Substrate for NO Synthase
L-Hydroxy arginine dihydrochloride is a substrate for nitric oxide synthase (NOS), playing a crucial role in the production of nitric oxide from L-arginine. This compound is utilized in biochemical research to investigate the enzymatic pathways of NO synthesis and its physiological implications. Its applications extend to studies exploring vascular function, signal transduction, and the impact of nitric oxide in various biological systems. -
nNOS Inhibitor
NOS1-IN-1 is a selective and cell-permeable inhibitor of neuronal nitric oxide synthase (nNOS), displaying a Ki of 120 nM. This compound demonstrates significant selectivity, with a 2617-fold preference over endothelial nitric oxide synthase (eNOS) and a 325-fold selectivity over inducible nitric oxide synthase (iNOS), evidenced by Ki values of 39 μM and 325 μM, respectively. NOS1-IN-1 is valuable for research on neurological disorders, including cerebral palsy, by enabling the exploration of nNOS-related pathways in disease mechanisms. -
NO Synthase Inhibitor
NOS-IN-1 is a potent and orally bioavailable inhibitor of nitric oxide synthase (NOS) isoforms, demonstrating inhibitory constants (IC50) of 0.1 μM for human inducible NOS (hiNOS), 1.1 μM for endothelial NOS (heNOS), and 0.2 μM for neuronal NOS (hnNOS). This compound is valuable for studying nitric oxide signaling pathways and exploring therapeutic options in diseases associated with dysregulated nitric oxide levels, such as cardiovascular disorders and neurodegenerative diseases. Its selective inhibition of NOS isoforms can aid in elucidating the specific roles of nitric oxide in various biological processes. -
NOS Inhibitor
TRIM is a potent nitric oxide synthase (NOS) inhibitor, selectively targeting neuronal nitric oxide synthase (nNOS) in mouse cerebellar samples and inducible nitric oxide synthase (iNOS) in rat lung tissues, with IC50 values of 28.2 µM and 27.0 µM, respectively. This compound exhibits significant antidepressant and anxiolytic-like properties, making it valuable for research into depression and anxiety disorders. TRIM serves as an important tool for investigations into NOS-related pathways and their implications in neuropsychiatric conditions. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-1 is a potent inhibitor targeting the interaction between SPSB2 and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (KD) of 4.4 nM. This cyclic peptide demonstrates resistance to proteolytic degradation by pepsin, trypsin, and α-chymotrypsin, ensuring stability in biological environments. Additionally, it maintains stability in human plasma and oxidative conditions, making it a valuable tool for studying iNOS-related pathways in inflammation and other biological processes. -
iNOS/Nf-Κb Inhibitor
Hymenoxin is a dual inhibitor of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 42.7 μM and 85.5 μM, respectively. This compound demonstrates the capacity to reduce oxidative stress by 16% at a concentration of 125 μg/mL. Hymenoxin is primarily utilized in research focused on inflammatory responses and related signaling pathways. Its inhibitory effects on key regulators make it valuable for studies investigating the roles of iNOS and NF-κB in various disease models. -
NOS Inhibitor
Vinyl-L-NIO hydrochloride is a selective inhibitor of nitric oxide synthase (NOS), effectively reducing nitric oxide production. By targeting the NOS enzyme, this compound serves as a valuable tool for investigating the role of nitric oxide in various biological processes. Its application extends to studies related to cardiovascular function, neurobiology, and inflammation research. -
NOS1Inhibitor
ARL 17477 is a dual inhibitor targeting neuronal nitric oxide synthase (NOS1) and the autophagy-lysosomal system. This compound exhibits significant anticancer activity and effectively inhibits tumor growth, particularly in KRAS-mutated cancers. Its potential applications include studies on cancer progression and therapeutic resistance, making it a valuable tool in cancer research. -
NO Synthase Inhibitor
Asymmetric dimethylarginine dihydrochloride is a potent inhibitor of nitric oxide synthase (NOS). By decreasing nitric oxide (NO) production, it plays a significant role in the study of endothelial dysfunction and related cardiovascular diseases. This compound is instrumental in research focused on elucidating the pathways involved in vascular health and hypertension. -
NOS Inhibitor
1,4-PBIT dihydrobromide is a potent inhibitor of nitric oxide synthases (NOS), demonstrating Ki values of 7.6 nM for inducible NOS (iNOS), 360 nM for endothelial NOS (eNOS), and 16 nM for neuronal NOS (nNOS). This compound serves as a valuable tool for investigating nitric oxide signaling pathways and assessing the role of NOS in various biological contexts. It is applicable in studies related to inflammation, neurobiology, and cardiovascular research. -
iNOS Inhibitor
AE-ITU dihydrobromide is a selective inhibitor of inducible nitric oxide synthase (iNOS). This compound has been shown to attenuate liver dysfunction induced by endotoxaemia in rat models, demonstrating its potential in studies related to inflammatory responses and liver pathology. AE-ITU dihydrobromide is valuable for researchers investigating the role of nitric oxide in various biological processes and therapeutic interventions. -
Cytotoxin
Banoxantrone, a hypoxia-selective cytotoxin, functions as a potent inhibitor of topoisomerase II after undergoing reduction to AQ4. It selectively targets and induces cell death in hypoxic environments through an iNOS-dependent mechanism. Additionally, Banoxantrone demonstrates significant cytotoxicity and synergizes with radiation to enhance its therapeutic effects, making it useful in cancer research focused on hypoxic tumors. -
eNOS Enhancer
AVE-9488 is an eNOS enhancer that promotes the upregulation of endothelial nitric oxide synthase (eNOS) expression, leading to increased nitric oxide (NO) production. This compound has demonstrated protective effects on the heart against ischemia-reperfusion injury by reducing myocardial damage and lowering reactive oxygen species levels. AVE-9488 is valuable for research focused on cardiovascular protection and the modulation of nitric oxide signaling pathways. -
NO Synthase Inhibitor
Curvularin is a potent inhibitor of inducible nitric oxide synthase (iNOS), demonstrating a half-maximal inhibitory concentration (IC50) of 9.5 µM. Isolated from the fungus Curvularia lunata, this mycotoxin is utilized in research to explore its effects on nitric oxide production in inflammatory responses. Curvularin's unique properties make it a valuable tool for investigating various biological processes and therapeutic applications related to iNOS inhibition. -
ZLc-002 S-enantiomer
(S)-ZLc002 is the S-enantiomer of ZLc-002, a selective inhibitor of neuronal nitric oxide synthase (nNOS) and its interaction with Capon. This compound demonstrates significant anti-inflammatory effects by suppressing inflammatory nociception and alleviating chemotherapy-induced neuropathic pain. It serves as an important tool for researchers studying pain mechanisms and potential therapeutic interventions in neuropathic conditions. -
iNOS Inhibitor
L-NIL hydrochloride is a selective inhibitor of inducible nitric oxide synthase (iNOS), demonstrated to have an IC50 of 3.3 μM in murine models. By inhibiting iNOS, L-NIL hydrochloride effectively reduces the production of nitric oxide, a key mediator in various inflammatory processes. This compound is utilized in research focused on inflammation, neurodegeneration, and associated pathologies where modulation of nitric oxide levels is critical. -
iNOS Inhibitor
AMT hydrochloride is a selective inhibitor of inducible nitric oxide synthase (iNOS), with a Ki value of 4.2 nM. This compound effectively modulates nitric oxide production, making it a valuable tool for studying inflammatory responses and related signaling pathways. It is applicable in research examining the role of iNOS in various physiological and pathological conditions. -
NOS Inhibitor
D-NAME hydrochloride is a potent nitric oxide synthase (NOS) inhibitor. By inhibiting NOS activity, D-NAME hydrochloride effectively reduces nitric oxide production, making it a valuable tool for studying the role of nitric oxide in various physiological and pathological processes. This reagent can be applied in research related to cardiovascular disease, neurodegeneration, and inflammatory responses. -
Nonenzyme Glycation Inhibitor
Flazin is a non-enzymatic protein glycation inhibitor that targets glycation processes and peroxynitrite (ONOO-). It exhibits an IC50 value of 85.31 μM in inhibiting bovine serum albumin (BSA) glycation and an EC50 value of 71.99 μM for ONOO-. Flazin is valuable in research related to diabetes and neurodegenerative disorders and functions as a lipid droplet regulator, making it relevant for studies on lipid metabolism disorders. Additionally, it serves as an inhibitor of xanthine oxidase (XOD), further expanding its utility in various biochemical applications. -
NO Inhibitor
Carboxy-PTIO is a highly effective nitric oxide (NO) scavenger, facilitating the rapid reaction with NO to generate nitrogen dioxide (NO2). This compound demonstrates significant biological activity in preventing hypotension and endotoxic shock, particularly in lipopolysaccharide-stimulated rat models. Carboxy-PTIO serves as a valuable tool in research focused on the roles of nitric oxide in various physiological and pathological processes. -
NO Synthase Inhibitor
Syzalterin is a potent inhibitor of nitric oxide synthase, demonstrating an IC50 value of 1.87 μg/mL. This compound effectively reduces NO production, making it valuable for research focused on nitric oxide-related signaling pathways and their implications in various physiological and pathological processes. Syzalterin can be utilized in studies exploring cardiovascular function, neurobiology, and inflammatory responses. -
NO Synthase Inhibitor
Cauloside C is a triterpene glycoside that acts as an inhibitor of nitric oxide synthase (NOS). It demonstrates significant anti-inflammatory properties by reducing the expression of inducible nitric oxide synthase (iNOS) and downregulating proinflammatory cytokines. This compound is a valuable tool for research focused on inflammation and related signaling pathways. -
NO Inhibitor
Futoquinol is a neolignan that acts as a nitric oxide (NO) inhibitor, derived from the dried aerial parts of Piper kadsura. This compound demonstrates potent inhibition of NO production in microglial cells, highlighting its potential in modulating neuroinflammatory processes. Futoquinol is valuable for research applications focused on neuroinflammation and related neurological disorders. -
NO Inhibitor
Panaxcerol B is a monogalactosyl monoacylglyceride characterized as a nitric oxide (NO) inhibitor. It exhibits an IC50 of 59.4 μM in inhibiting NO production in lipopolysaccharide-stimulated RAW264.7 macrophage cells. This compound is valuable for research applications focused on inflammatory responses and related signaling pathways. -
NO Synthase Inhibitor
3-Amino-1,2,4-triazine acts as an inhibitor of nitric oxide (NO) synthase, thereby impacting NO production and modulating associated cellular signaling pathways. This compound is relevant for studying the role of NO in various biological processes and may aid in research applications focused on vascular function, neurobiology, and inflammation. Its inhibitory effects on nitrite secretion further enhance its utility in investigating nitric oxide-related mechanisms in biological systems. -
NO Inhibitor
(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid is a lanostane triterpenoid that serves as a nitric oxide (NO) inhibitor, demonstrating potent inhibitory effects on LPS-induced BV-2 microglia cells with an IC50 of 9.55 µM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on neuroinflammation and related pathways. -
iNOS Inhibitor
BYK 191023 dihydrochloride is a selective inhibitor of inducible nitric-oxide synthase (iNOS), targeting the enzyme's catalytic center. This compound plays a critical role in research focused on the regulation of nitric oxide production and its implications in inflammatory responses. Its application is vital for studying both in vitro and in vivo effects mediated by iNOS, making it an essential tool for investigations into related pathological conditions. -
hDDAH-1 Inhibitor
hDDAH-1-IN-1 is a potent and selective inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), functioning through non-amino acid catalytic site inhibition, with an inhibition constant (Ki) of 18 μM. By inhibiting DDAH, this compound regulates the metabolism of asymmetric dimethylarginine (ADMA), influencing nitric oxide production. This makes hDDAH-1-IN-1 valuable in research applications related to cardiovascular diseases, neurodegenerative disorders, and conditions where nitric oxide dysregulation plays a critical role. -
hDDAH-1 Inhibitor
hDDAH-1-IN-2 sulfate is a selective inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1). This compound has demonstrated low toxicity and high cell viability, making it suitable for advanced research applications. It is valuable for investigating the role of hDDAH-1 in cardiovascular diseases and other physiological processes influenced by nitric oxide metabolism. -
iNOS Inhibitor
L-NIL dihydrochloride is an inducible nitric oxide synthase (iNOS) inhibitor, exhibiting an IC50 value of 3.3 μM for miNOS. This compound demonstrates significant biological activity by curtailing nitric oxide production, which plays a critical role in inflammatory processes. L-NIL dihydrochloride is widely utilized in research to investigate the implications of nitric oxide in various pathophysiological conditions, making it an essential tool for studies related to inflammation and immune response. -
hDDAH-1 Inhibitor
hDDAH-1-IN-1 TFA is a selective non-amino acid inhibitor targeting human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), exhibiting a Ki of 18 μM. This compound demonstrates potent inhibition of the enzyme's catalytic activity, making it a valuable tool for studying the regulation of nitric oxide synthase and the metabolism of asymmetric dimethylarginines. Research applications include investigations into cardiovascular diseases, endothelial function, and polyamine metabolism. -
iNOS Inhibitor
iNOS inhibitor-10 is a selective inhibitor of inducible nitric oxide synthase (iNOS) with an IC50 of 65 nM. It exhibits antiproliferative effects against triple-negative breast cancer cells, making it a valuable tool for research on cancer biology and therapeutic approaches targeting the iNOS pathway. Its application in studying the role of nitric oxide in tumor progression highlights its potential relevance in cancer research. -
NO Synthase Inhibitor
Harzianol L is an inhibitor of nitric oxide (NO) synthase, derived from the Trichoderma species SCSIOW21. This compound has demonstrated the ability to inhibit NO production, contributing to its anti-inflammatory effects. Harzianol L is useful in research applications focused on studying inflammatory processes and the regulation of nitric oxide in various biological contexts. -
DDAH Inhibitor
Methyl-L-NIO hydrochloride is a selective inhibitor of dimethylarginine dimethylaminohydrolase (DDAH), exhibiting an IC50 value of 70 μM. This compound also demonstrates inhibitory effects on nitric oxide synthase (NOS) isoforms, with inhibition rates at 100 μM of 77% for neuronal NOS (nNOS), 20% for endothelial NOS (eNOS), and 72% for inducible NOS (iNOS). At a concentration of 1 mM, Methyl-L-NIO achieves 100% inhibition of both nNOS and iNOS, and 85% inhibition of eNOS. This reagent is valuable for research applications involving the modulation of nitric oxide signaling pathways and the study of DDAH activity. -
NO Synthase Inhibitor
Harzianol K is a harziane-type diterpene derivative that acts as an inhibitor of nitric oxide synthase (NO Synthase). This compound demonstrates significant inhibitory effects on nitric oxide production, making it a valuable tool for research in the anti-inflammatory field. Its unique origin from deep-sea sediment fungus Trichoderma sp. SCSIOW21 adds to its potential for exploring various biological pathways associated with inflammation. -
Immunosuppressive Agent
3,4-DAA is an orally active anthranilic acid derivative that acts as an immunosuppressive agent. It effectively mitigates colitis severity by inhibiting Th1 cell responses and promoting the expression of Th2 cytokines, as well as inducing CD4+CD25+ T cell expression. Additionally, 3,4-DAA reduces the expression of inducible nitric oxide synthase (iNOS) and the release of nitric oxide (NO) from EOC20 cells stimulated by IFN-γ and lipopolysaccharide. This makes it a valuable tool for research in immunology and inflammatory diseases. -
NO Synthase Inhibitor
Camstatin is a potent inhibitor of neuronal nitric oxide (NO) synthase, functioning through its interaction with calmodulin. This 25-residue fragment derived from the IQ motif of PEP-19 demonstrates significant activity in modulating NO production. Camstatin is valuable for research applications focusing on nitric oxide signaling pathways and their role in various neurological conditions.
